Other Events ·
Kazia Therapeutics Limited announced the filing of a provisional patent application for a novel therapeutic strategy…
KZIAKazia Therapeutics Ltd
Kazia Therapeutics Limited announced the filing of a provisional patent application for a novel therapeutic strategy designed to prevent metastatic recurrence in patients with high-risk early-stage triple-negative breast cancer. The filing is supported by preclinical data from a model replicating high-risk early-stage TNBC, where adjuvant paxalisib reduced residual disease and local recurrence by 95% and lung metastatic burden by 40%. Complementary translational studies on patient tumor samples showed paxalisib completely disrupted circulating tumor cell clusters. These findings, combined with encouraging preliminary data from an ongoing Phase Ib study in advanced metastatic TNBC, strengthen the rationale for advancing paxalisib across multiple disease stages. The company is actively evaluating opportunities to broaden clinical development into earlier-stage TNBC and expects to provide additional details on its development strategy in the near term. Kazia Therapeutics is an oncology-focused biotechnology company developing therapies that reprogram cancer biology and restore anti-tumor immunity.